Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome

This study has been completed.
Sponsor:
Collaborator:
Dutch Heart Foundation
Information provided by (Responsible Party):
G.B. Braam, University of Alberta
ClinicalTrials.gov Identifier:
NCT00356733
First received: July 25, 2006
Last updated: November 30, 2011
Last verified: November 2011
  Purpose

Erythropoietin (EPO) treatment in patients with the severe cardiorenal syndrome increases cardiac performance and decreases progression of renal failure by dampening the main driving forces of the cardiorenal syndrome in part via non-erythropoietic pathways.

I. Does EPO administration to patients with the severe cardiorenal syndrome increase cardiac performance and decrease progression of renal disease?

II. Does EPO treatment affect the main driving forces of the cardiorenal connection, that is, dampen the activated renin-angiotensin system (RAS), attenuate increased reactive oxygen species (ROS), normalize increased sympathetic activity, and decrease inflammation?

III. Does EPO treatment positively affect the cell function of patients with the cardiorenal syndrome:

  1. are gene expression signatures of leukocytes positively influenced by EPO treatment,
  2. does EPO shift the Jak/STAT pathway to a less pro-inflammatory profile in monocytes, and
  3. are function and number of endothelial progenitor cells (EPCs) affected by treatment with EPO in the cardiorenal syndrome?

IV. Can the direct actions of EPO be differentiated from the effects on hemoglobin levels?


Condition Intervention Phase
Heart Failure, Congestive
Renal Insufficiency, Chronic
Drug: Erythropoietin administration
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome

Resource links provided by NLM:


Further study details as provided by UMC Utrecht:

Primary Outcome Measures:
  • changes in gene-arrays, EPC and biomarkers panels [ Time Frame: 14 days, 6 and 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • cardiac performance and renal function [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
  • QoL [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]

Enrollment: 62
Study Start Date: January 2007
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EPO rise
EPO administration
Drug: Erythropoietin administration
50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
Experimental: EPO stable
EPO and stable Hemoglobin
Drug: Erythropoietin administration
50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
No Intervention: control
standard treatment

Detailed Description:

The combination of renal and cardiac failure is associated with an extraordinary cardiovascular morbidity and mortality. We propose that the severe cardiorenal syndrome (SCRS), the pathophysiological condition in which there is combined cardiac and renal dysfunction, amplifies the progression of the failure of the individual organ. Central in the pathogenesis of the cardiorenal syndrome is enhanced oxidative stress, inflammation and enhanced activation of the renin-angiotensin and sympathetic nervous system. Chronic renal failure is further accompanied by anemia due to a gradual decline in erythropoietin (EPO) formation by the diseased kidneys and/or by EPO resistance. Recently, the interest in EPO is increasing since it serves not only as a hematopoietic factor, but also has been shown to increase the number of endothelial progenitor cells (EPCs) in end-stage renal disease (ESRD) patients. Moreover, EPO is involved in signaling via Akt to support NO release and may act as an anti-apoptotic. Some evidence supports the idea that EPO improves cardiac and renal function in the syndrome; however, no information is available about the mechanisms. The hypothesis of the present proposal is that EPO treatment in patients with the severe cardiorenal syndrome increases cardiac performance and decreases progression of renal failure in part via non-erythropoietic pathways. The questions are whether EPO administration to patients with the severe cardiorenal syndrome:

  1. increases cardiac performance and decreases progression of renal disease,
  2. dampens the activated RAS and sympathetic nervous system, attenuates increased ROS and decreases signs of inflammation and
  3. positively influences cell function of leukocytes (assessed by gene expression signatures), of monocytes (shifts to a less pro-inflammatory Jak/Stat signaling) and of EPC (number and function).

This will be addressed in a two-part clinical study in patients with combined moderate chronic renal failure and heart failure (New York Heart Association [NYHA] II-III). First, patients will be treated with EPO for 12 months, and hemoglobin levels will be kept constant at initial levels or will be allowed to increase; another group will be left untreated. Besides cardiac and renal function, the RAS, the SNS, and ROS/NOS balance and inflammatory parameters will be assessed. Furthermore, cell function of leukocytes (gene expression signatures), monocytes (Jak/STAT activation) and EPCs (number and function) will be studied. Taken together, central in the proposal is that combined heart-kidney failure is accompanied by relative or absolute EPO dysfunction, disproportional to the degree of renal failure and that treatment with EPO improves cardiac performance and renal function.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with moderate renal failure (glomerular filtration rate [GFR] by Cockroft formula of 20-70 ml/min)
  • Patients with heart failure NYHA class II-III-IV
  • Hemoglobin (Hb) between 6.4 - 7.8 mmol/L in men and between 6.0 - 7.4 mmol/L in women
  • Age > 18 years, < 80 years
  • Written informed consent must be obtained from the subject or legally accepted representative before study-specific procedures, including screening procedures, are performed.

Exclusion Criteria:

  • Therapy within 1 year before randomisation or any planned erythropoietic therapy between randomisation and study day 1
  • Known intolerance to EPO administration
  • Previously suspected of or confirmed to have neutralizing antibodies to recombinant human erythropoietin (rHuEPO)
  • Uncontrolled hypertension (RR > 160 systolic, >100 diastolic)
  • Forms of secondary hypertension other than renal hypertension
  • Uncontrolled diabetes (HbA1c > 8.0 %)
  • Primary dyslipidemia
  • Kidney transplantation
  • Proteinuria > 3.5 g/L
  • Acute renal failure or rapidly progressive glomerulonephritis
  • Hyperparathyroidism (parathyroid hormone [PTH] > 40)
  • Bleeding or haemolysis as a cause of anaemia
  • Deficiency of iron, folate, and/or vitamin B12
  • Presence of chronic inflammatory disease or clinically significant infection
  • Haematologic malignancy or solid tumour < 5 years ago
  • Chronic liver disease
  • Haemoglobinopathies
  • Alcohol and/or drug abuse
  • Enrolment in another study
  • Child bearing potential (pre-menopausal woman who is not using adequate contraceptive precautions)
  • Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00356733

Locations
Netherlands
Meander Medical Center Amersfoort
Amersfoort, Utrecht, Netherlands, 3800 BM
Univ. Medical Center Utrecht
Utrecht, Netherlands, 3508 GA
Sponsors and Collaborators
UMC Utrecht
Dutch Heart Foundation
Investigators
Principal Investigator: Branko Braam, MD, PhD UMC Utrecht, The Netherlands
Principal Investigator: Carlo AJ Gaillard, MD, PhD Meander Medical Center Amersfoort, The Netherlands
Study Director: Pieter AF Doevendans, MD, PhD UMC Utrecht, The Netherlands
  More Information

No publications provided by UMC Utrecht

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: G.B. Braam, Associate Professor of Medicine, University of Alberta
ClinicalTrials.gov Identifier: NCT00356733     History of Changes
Other Study ID Numbers: NHS-2005B192
Study First Received: July 25, 2006
Last Updated: November 30, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by UMC Utrecht:
cardiorenal syndrome
erythropoietin
Heart Failure, Congestive
Renal Insufficiency, Chronic

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Renal Insufficiency, Chronic
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Epoetin Alfa
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014